| 07/07/2026 7:15 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/26/2026 4:20 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/18/2026 3:35 PM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 10:17 AM | Caligan Partners LP (1727492) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 05/15/2026 5:28 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 05/12/2026 6:35 AM | SAB Biotherapeutics (1833214) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/04/2026 3:35 PM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/01/2026 3:57 PM | MILLENNIUM MANAGEMENT LLC (1273087) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 04/22/2026 7:13 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/31/2026 4:35 PM | SAB Biotherapeutics (1833214) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/25/2026 3:35 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for SABSW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 03/23/2026 3:25 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13D/A | |
| 03/10/2026 6:35 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/09/2026 4:10 PM | SAB Biotherapeutics (1833214) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/17/2026 7:47 AM | RTW INVESTMENTS, LP (1493215) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G/A | |
| 02/05/2026 3:45 PM | Bausch Christoph Lawrence (1889981) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 3:50 PM | Reich Samuel J (1394645) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/05/2026 3:55 PM | SAB Biotherapeutics (1833214) Issuer Sullivan Eddie Joe (1889712) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/22/2026 3:34 PM | PERCEPTIVE ADVISORS LLC (1224962) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 01/07/2026 11:15 PM | SAB Biotherapeutics (1833214) Filer | Form EFFECT | |
| 01/07/2026 3:40 PM | SAB Biotherapeutics (1833214) Issuer ZACCARDELLI DAVID (1627642) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 3:41 PM | Jain Rita (1707797) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/07/2026 3:35 PM | SAB Biotherapeutics (1833214) Issuer ZACCARDELLI DAVID (1627642) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 01/07/2026 3:36 PM | Jain Rita (1707797) Reporting SAB Biotherapeutics (1833214) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 01/07/2026 7:30 AM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/30/2025 9:08 AM | SAB Biotherapeutics (1833214) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 12/18/2025 3:45 PM | Ellias Helen K. (2001600) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:50 PM | Lucera Erick (1697616) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:53 PM | Polvino William James (1889459) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:40 PM | Link David (2085171) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/18/2025 3:43 PM | Giberson Scott (1937585) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 3:30 PM | SAB Biotherapeutics (1833214) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 12/12/2025 3:45 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/12/2025 3:45 PM | SAB Biotherapeutics (1833214) Filer | Form 424B3 | |
| 10/03/2025 3:26 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13D | |
| 10/03/2025 3:30 PM | SAB Biotherapeutics (1833214) Subject Vivo Opportunity Fund Holdings, L.P. (1930214) Filed by | Form SCHEDULE 13G | |
| 10/03/2025 3:05 PM | Commodore Capital LP (1831942) Filed by SAB Biotherapeutics (1833214) Subject | Form SCHEDULE 13G | |
| 10/01/2025 3:35 PM | Moin Andrew (1996040) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2025 3:06 PM | Petry John (1618702) Reporting SAB Biotherapeutics (1833214) Issuer Sessa Capital (0) Master Sessa Capital GP, LLC (1618699) Reporting Sessa Capital IM GP, LLC (1618700) Reporting Sessa Capital IM, L.P. (1595849) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/30/2025 11:15 PM | SAB Biotherapeutics (1833214) Filer | Form EFFECT | |
| 09/30/2025 3:35 PM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Your $29.97 book is free today (Ad) Why Some Traders Skip Stocks Entirely
You don't need a big account to trade options.
In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up.
This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. Normally $29.97. Today it's free. Grab your copy now. |
| 09/26/2025 3:45 PM | SAB Biotherapeutics (1833214) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/22/2025 4:00 PM | Kropotova Alexandra (1825323) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/22/2025 4:15 PM | SAB Biotherapeutics (1833214) Filer | Form S-3/A | |
| 09/02/2025 4:25 PM | SAB Biotherapeutics (1833214) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 08/29/2025 4:23 PM | SAB Biotherapeutics (1833214) Filer | Form DEF 14A | |
| 08/28/2025 4:10 PM | SAB Biotherapeutics (1833214) Issuer To Lucy (2032049) Reporting To Lucy (2032049) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/28/2025 4:15 PM | Reich Samuel J (1394645) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/19/2025 3:30 PM | SAB Biotherapeutics (1833214) Filer | Form PRE 14A | |
| 08/07/2025 6:30 AM | SAB Biotherapeutics (1833214) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/24/2025 3:30 PM | Moin Andrew (1996040) Reporting SAB Biotherapeutics (1833214) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/24/2025 3:31 PM | Petry John (1618702) Reporting SAB Biotherapeutics (1833214) Issuer Sessa Capital (0) Master Sessa Capital GP, LLC (1618699) Reporting Sessa Capital IM GP, LLC (1618700) Reporting Sessa Capital IM, L.P. (1595849) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |